References 1. Cassileth BR, Lusk EJ, Guerry D, et al. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med 1991; 324: 1180–1185.[Abstract] 2. Richardson MA, Russell NC, Sanders T, et al. Assessment of outcomes at alternative medicine cancer clinics: a feasibility study. J Altern Complement Med 2001; 7: 19–32. 3. Italian Study Group for the Di Bella Multitherapy Trials. Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. BMJ 1999; 318: 224–228. 4. Buiatti E, Arniani S, Verdecchia A, et al. Results from a historical survey of the survival of cancer patients given Di Bella multitherapy. Cancer 1999; 86: 2143–2149. 5. Lyall D, Schwartz M, Herter FP, Hudson PB, et al. Treatment of cancer by the method of Revici. JAMA 1965; 194: 279–280. 6. Eidem WK. The Doctor Who Cures Cancer. New York, NY: Sullivan & Foster Publishing; 1997. 7. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987; 13 ( Suppl 1): 37–43. 8. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999; 74: 137–145. 9. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 1976; 73: 3685–3689. 10. Cameron E, Pauling L, Leibovitz B. Ascorbic acid and cancer: a review. Cancer Res 1979; 39: 663–681.[Abstract] 11. Creagan ET, Moertel CG, O’Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301: 687–690.[Abstract] 12. Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985; 312: 137–141.[Abstract] 13. Padayatty SJ, Levine M. New insights into the physiology and pharmacology of vitamin C. CMAJ 2001; 164: 353–355. 14. Smart CR, Hogle HH, Vogel H, et al. Clinical experience with nordihydroguaiaretic acid–"chaparrel tea" in the treatment of cancer. Rocky Mt Med J 1970; 67: 39–43. 15. Chlebowski RT, Bulcavage L, Grosvenor M, et al. Hydrazine sulfate influence on nutritionalstatus and survival in non-small-cell lung cancer. J Clin Oncol 1990; 8: 9–15.[Abstract] 16. Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994; 12: 1126–1129.[Abstract] 17. Loprinzi CL, Kuross SA, O’Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994; 12: 1121–1125.[Abstract] 18. Kosty MP, Fleishman SB, Herndon JE, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994; 12: 1113–1120.[Abstract] 19. Moertel CG, Fleming TR, Rubin J, et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 1982; 306: 201–206.[Abstract] 20. Lane IW, Comac L. Sharks Don’t Get Cancer. Garden City Park, NY: Avery Publishing; 1993. 21. Sharks Don’t Get Cancer. "60 Minutes." CBS television. February 28, 1993. 22. Miller DR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998; 16: 3649–3655.[Abstract] 23. Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975; 141: 427–439. 24. Falardeau P, Champagne P, Poyet P, et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001; 28: 620–625. 25. Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002; 13: 1259–1263. 26. Hildenbrand GL, Hildenbrand LC, Bradford K, Cavin SW. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review. Altern Ther Health Med 1995; 1: 29–37. 27. Zollman C, Rees R. Disputes conclusions in Hildenbrand study [letter]. Altern Ther Health Med 1997; 2: 14–15. 28. Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutr Cancer 1999; 33: 117–124. 29. Risberg T, Lund E, Wist E, et al. The use of non-proven therapy among patients treated in Norwegian oncological departments. A cross-sectional national multicentre study. Eur J Cancer 1995; 31: 1785–1789. 30. Risberg T, Vickers A, Bremnes RM, et al. Does use of alternative medicine predict survival from cancer? Eur J Cancer 2003; 39: 372–377. 31. Gellert GA, Maxwell RM, Siegel BS. Survival of breast cancer patients receiving adjunctive psychosocial support therapy: a 10-year follow-up study. J Clin Oncol 1993; 11: 66–69.[Abstract] 32. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989; 2: 888–891. 33. Cunningham AJ, Edmonds CV, Jenkins GP, et al. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology 1998; 7: 508–517. 34. Kraemer H, Spiegel D. Cunning but careless: analysis of a non-replication. Psychooncology 1999; 8: 273–275. 35. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001; 345: 1719–1726. 36. Cassileth BR, Schraub S, Robinson E, Vickers A. Alternative medicine use worldwide: the International Union Against Cancer survey. Cancer 2001; 91: 1390–1393. 37. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. JAMA 1996; 276: 313–318.[Abstract] 38. Walker LG, Walker MB, Ogston K, et al. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer 1999; 80: 262–268. 39. Grealish L, Lomasney A, Whiteman B. Foot massage. A nursing intervention to modify the distressing symptoms of pain and nausea in patients hospitalized with cancer. Cancer Nurs 2000; 23: 237–243. 40. Cassileth BR, Vickers AJ, Magill LA. Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial. Cancer 2003; 98: 2723–2729. 41.Alimi D, Rubino C, Pichard-Leandri E, et al. Analgesic effect of auricular acupuncture for cancer pain: randomized, blinded, controlled trial. J Clin Oncol 2003; 21: 4120–4126. 42. Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2001; 50: 353–357. 43. Goebell PJ, Otto T, Suhr J, Rubben H. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 2002; 168: 72–75. 44. Lenartz D, Dott U, Menzel J, et al. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 2000; 20: 2073–2076. 45. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001; 37: 23–31. 46. Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 2003; 92: 375–378. 47. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990; 31: 261–268. 48. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994; 343: 1122–1126. 49. Yan J, Vetvicka V, Xia Y, et al. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 1999; 163: 3045–3052. 50. Cheung NK, Modak S, Vickers A, Knuckles B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 2002; 51: 557–564. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.